Hospital
Community Health Network, INC
Community Health Network, INC was paid $32.97M by Medicaid between Jan 2018 and Nov 2024, across 102 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoCOMMUNITY HEALTH NETWORK, INC
INDIANAPOLIS, IN 46256
INDIANAPOLIS, IN 46256
33aNPI1619163854assigned 09/21/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.97M
24GClaims557,474
24DCodes billed102
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#10 of 69
Median peer was paid$9.76M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,081 | $2.04M | |
| 2019 | 60,703 | $3.38M | |
| 2020 | 51,801 | $3.21M | |
| 2021 | 84,963 | $5.59M | |
| 2022 | 121,317 | $7.94M | |
| 2023 | 97,879 | $6.68M | |
| 2024incomplete | 57,730 | $4.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 97,865 | 81,877 | $13.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 49,091 | 43,306 | $7.09M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 6.0% | 30,683 | 24,453 | $1.96M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 36,736 | 29,627 | $1.51M |
| 71045 | Radiologic examination, chest; single view | 4.2% | 9,316 | 7,783 | $1.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 6,324 | 5,325 | $931K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,535 | 1,246 | $601K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 16,915 | 13,073 | $599K |
| 43235 | 1.8% | 364 | 318 | $593K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 79,018 | 64,735 | $355K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 4,190 | 3,431 | $338K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 2,208 | 1,625 | $336K |
90 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,491 | $327K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,486 | $297K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,592 | $233K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,815 | $223K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,781 | $216K |
| 74018 | <1% | 1,099 | $204K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,657 | $180K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,036 | $178K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,014 | $131K |
| 36415 | Collection of venous blood by venipuncture | <1% | 50,701 | $129K |
| 81025 | <1% | 20,089 | $101K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 130 | $85K |
| 97165 | <1% | 569 | $83K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,485 | $79K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,469 | $75K |
| 99218 | <1% | 171 | $66K | |
| 99217 | <1% | 185 | $61K | |
| 59025 | Fetal non-stress test | <1% | 169 | $55K |
| 84484 | <1% | 7,397 | $51K | |
| 97162 | <1% | 289 | $42K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,747 | $38K |
| 92523 | <1% | 247 | $37K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,643 | $37K |
| 81001 | <1% | 20,100 | $37K | |
| G0378 | Hospital observation service, per hour | <1% | 267 | $35K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 717 | $33K |
| 43770 | <1% | 26 | $32K | |
| 83690 | <1% | 8,894 | $30K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 777 | $29K |
| 80076 | <1% | 5,296 | $26K | |
| 87088 | <1% | 3,783 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 400 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 222 | $15K |
| 74246 | <1% | 82 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 291 | $13K |
| 99221 | <1% | 26 | $13K | |
| 77066 | Tomosynthesis, mammo | <1% | 44 | $13K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 40 | $11K |
| 74220 | <1% | 98 | $11K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 81 | $9K |
| 97161 | <1% | 57 | $9K | |
| 76642 | <1% | 54 | $8K | |
| 99224 | <1% | 134 | $6K | |
| 80047 | <1% | 1,352 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 19 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 375 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 23 | $3K |
| 97163 | <1% | 16 | $2K | |
| 87634 | <1% | 31 | $2K | |
| 85027 | <1% | 514 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 209 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 28 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $651.46 |
| 82553 | <1% | 505 | $593.49 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 55 | $524.28 |
| 96376 | <1% | 293 | $430.92 | |
| 97803 | <1% | 15 | $409.82 | |
| 87641 | <1% | 26 | $386.01 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 57 | $330.61 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 156 | $277.37 |
| 83880 | <1% | 17 | $274.82 | |
| 94760 | <1% | 13 | $218.22 | |
| 85014 | <1% | 223 | $208.01 | |
| 85379 | <1% | 27 | $195.85 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22 | $184.80 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $149.34 |
| 80061 | Lipid panel | <1% | 21 | $139.48 |
| 81003 | <1% | 105 | $138.13 | |
| 82565 | <1% | 51 | $121.88 | |
| 84439 | <1% | 21 | $90.20 | |
| 82570 | <1% | 15 | $56.98 | |
| 84550 | <1% | 20 | $45.20 | |
| 84156 | <1% | 18 | $44.04 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 24 | $36.80 |
| 85610 | <1% | 12 | $23.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,080 | $22.20 |
| 86850 | <1% | 15 | $20.20 | |
| 86900 | <1% | 15 | $12.88 | |
| 86901 | <1% | 15 | $12.88 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,337 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 80 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 80 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 16 | $0.00 |
| 97802 | 0% | 149 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 303 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 29 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 22 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 86 | $0.00 |
| 64488 | 0% | 18 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLARD, HOLLY (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Community Health Network, INC | Indianapolis, IN | $161.73M |
| Community Hospital of Anderson & Madison County, INC | Anderson, IN | $32.30M |
| Community Hospital South, INC. | Indianapolis, IN | $27.35M |
| Fairbanks Hospital, INC. | Indianapolis, IN | $18.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.